Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET
Company Participants
Louise Wilkie - Investor Relations
Sandy Macrae - Chief Executive Officer
Rob Schott - Head of Development
Jason Fontenot - Chief Scientific Officer
Prathyusha Duraibabu - Chief Financial Officer
Bettina Cockroft - Chief Medical Officer
Mark McClung - Chief Operating Officer
Conference Call Participants
Gregory Harrison - Bank of America
Yanan Zhu - Wells Fargo
Harshita Polishetty - Barclays
Ritu Baral - Cowen and Company
Lisa Walter - RBC Capital
Maury Raycroft - Jefferies
Jason Shieh - H.C. Wainwright & Co.
Andreas Argyrides - Wedbush Securities
Operator
Ladies and gentlemen, thank you for standing by, and welcome to Sangamo Second Quarter 2022 Earnings Conference Call. [Operator Instructions] I would now like to turn the call over to your host, Louise Wilkie. You may begin.
Louise Wilkie
Good afternoon. I’m Louise Wilkie, Sangamo's Vice President, Investor Relations and Corporate Communication. Thank you for joining us on the call today. On this call, several members of the Sangamo executive leadership team, including Sandy Macrae, Chief Executive Officer; Mark McClung, Chief Operating Officer; Prathyusha Duraibabu, Chief Financial Officer; Jason Fontenot, Chief Scientific Officer; Rob Schott, Head of Development; and Bettina Cockroft, Chief Medical Officer. Slides from our corporate presentation can be found at our website, sangamo.com, under the Investors and Media section of the Events and Presentations page.
This call includes forward-looking statements regarding Sangamo's current expectations. These statements include, but are not limited to, statements related to the therapeutic and commercial potential of our product candidates. The anticipated plans and time lines of Sangamo and our collaborators for initiating and conducting clinical trials; posting and screening of patients and presenting clinical data, execution of our corporate and funding strategy, advancement of our product candidates, advancements of preclinical programs to the clinic, the sufficiency of our resources, our 2022 financial guidance, key milestones and catalysts, and other statements that are not historical facts.
Actual results may differ materially from what we discuss today. These statements are subject to certain risks and uncertainties that are discussed in our filings with the SEC, specifically in our annual report on Form 10-K for the fiscal quarter ended March 31, 2022, and our annual report on Form 10-K for the fiscal year ended December 31, 2021, as supplemented by our quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2022. The forward-looking statements stated today are made as of this date, and we undertake no duty to update such information, except as required by law. On this call, we discuss our non-GAAP operating expenses. Reconciliation of this measure to our GAAP operating expenses can be found in today's press release, which is available on our website.